Company* (Country; Symbol) | Company* (Country; Symbol) | Type/Product Area | Terms/Details (Date) |
FEBRUARY | |||
Biotage AB (Sweden; SSE:BIOT) | MultiSynTech GmbH* (Germany) | Agreements that grant Biotage distribution rights for all MultiSynTech peptide synthesis systems and to design and market a microwave-aided peptide synthesis system to increase yield and speed in peptide synthesis | Terms were not disclosed (2/17) |
Cell Therapeutics Inc. (CTIC) | IDIS Ltd.* (UK) | Collaboration to manage Cell Therapeutics' drug pixantrone on a named patient basis in Europe | Pixantrone will be supplied by IDIS to health care professionals for the treatment of individual patients with relapsing aggressive non-Hodgkin's lymphoma (2/10) |
OctoPlus NV (the Netherlands; Amsterdam:OCTO) | Galapagos NV (Belgium; BR:GLPG) | Contract to manufacture clinical trial material for Galapagos' Phase II study of Nanocort, a liposome formulation of prednisolone | Terms were not disclosed (2/12) |
Pluristem Therapeutics Inc. (PSTI) | Pharmicell Europe GmbH* (Germany) | Collaboration to distribute PLX-PAD, Pluristem's placental-derived adherent stromal cell product, to various clinical sites in Germany, in connection with Pluristem's upcoming clinical trials in critical limb ischemia | Financial terms were not disclosed (2/24) |
Siron Therapeutics Inc.* | Advanced Vision Research Inc.* | Agreement to co-promote within the U.S. AVR's MacuTrition oral retinal nutritional supplement and its NutriDox Convenience Kit for meibomian gland therapy | Terms were not disclosed (2/17) |
MARCH | |||
ArunA Biomedical Inc.* | Neuromics Inc.* | Agreement for the nonexclusive right to market and sell the ArunA hN2 Human Neural Cells and Neural Culture Medium to support applications in neurological research | Financial terms were not disclosed (3/24) |
Cel-Sci Corp. (AMEX:CVM) | Byron Biopharma* | Exclusive license to market and distribute the company's cancer drug Multikine in the Republic of South Africa | Byron will purchase $750,000 worth of stock from Cel-Sci and will make a payment of $125,000 in 12 months (3/9) |
NewBridge Pharmaceuticals* | ProStrakan (UK; LSE:PSK) | Exclusive license and supply deal for Sancuso in Turkey | Sancuso is a transdermal patch for the prevention of chemotherapy-induced nausea and vomiting; the agreement is an extension of an existing license in the Middle East and Africa (3/5) |
Novozymes Biopharma UK Ltd. (UK; LSE:NVZ) | GE Healthcare Life Sciences | License agreement that enables Novozymes to produce and deliver native, animal-free protein A using GE technology | Terms were not disclosed (3/9) |
Targeted Genetics Corp. (TGEN) | Celladon Corp.* | License and manufacturing agreements to enable Celladon to manufacture Mydicar through commercial manufacturing organizations or a commercial product development partner | Celladon will increase the payments to Targeted Genetics in the first six months of this year to support manufacturing for Phase III studies (3/2) |
APRIL | |||
EPIX Pharmaceuticals Inc. (EPIX) | Lantheus Medical Imaging Inc.* | Agreement for EPIX to sell U.S., Canadian and Australian rights to imaging agent MS-325, formerly marketed as Vasovist, for $28M | EPIX will pay $10.5M in obligations to former partner Bayer Schering Pharma AG, which marketed Vasovist (4/7) |
Laboratories Almirall SA* (Spain) | Recordati SpA* (Italy) | License agreement for the marketing and sales of silodosin, a compound indicated to treat the signs and symptoms of benign prostatic hyperplasia in Spain | Almirall will co-market the product together with Recordati Espana; terms were not disclosed (4/3) |
Transposagen Biopharmaceuticals Inc.* | Trans Genic Inc.* | Agreement for the non-exclusive rights to market Transposagen's products in Japan | Terms were not disclosed (4/15) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; BR = Brussels Stock Exchange; LSE = London Stock Exchange; SSE = Stockholm Stock Exchange. |